IDXX
IDEXX Laboratories, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -5.6% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 168 | 0 | 55.55M | $29.26B | +7 | −6 |
| Q1 2026 | 170 | +1 | 53.67M | $30.16B | +5 | −5 |
| Q4 2025 | 168 | +2 | 58.18M | $39.32B | +3 | — |
| Q3 2025 | 21 | +1 | 29.88M | $19.09B | +1 | −1 |
| Q2 2025 | 18 | 0 | 26.38M | $14.14B | +1 | −1 |
| Q1 2025 | 15 | -2 | 9.43M | $3.96B | — | −2 |
| Q4 2024 | 17 | -1 | 9.47M | $3.92B | — | −1 |
| Q3 2024 | 17 | +1 | 5.70M | $2.88B | +1 | — |
| Q2 2024 | 16 | — | 5.12M | $2.49B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 9.88M | — | $5.30B | 0.1% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 8.37M | — | $4.49B | 0.1% | n/c | 1 | SEC ↗ ×22 |
| 3 | State Street Global Advisors ✦ (passive) | 3.55M | -2.6% | $1.91B | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.46M | +2.3% | $1.32B | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 5 | T. Rowe Price ✦ | 536.10K | -73.0% | $287.53M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | Norges Bank ✦ (passive) | 413.83K | +18.9% | $221.95M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 7 | Fidelity (FMR) ✦ | 269.88K | — | $144.75M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 8 | AQR Capital Management ✦ | 223.32K | +27.0% | $118.69M | 0.1% | ▲ Add | 5 | SEC ↗ ×6 |
| 9 | Arrowstreet Capital ✦ | 206.14K | +8.0% | $110.56M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 10 | Wellington Management ✦ | 188.17K | -14.3% | $100.92M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 11 | Millennium Management ✦ | 78.78K | +99.4% | $42.25M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 59.20K | New | $31.75M | 0.1% | New | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 43.38K | +3946.8% | $23.27M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 14 | Gotham Asset Management ✦ | 34.66K | +69.5% | $18.59M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 22.66K | -90.5% | $12.15M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Marshall Wace ✦ | 20.00K | -81.9% | $10.73M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 9.70K | -71.8% | $5.20M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Bridgewater Associates ✦ | 2.62K | -23.6% | $1.41M | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $31.75M | 0.1% |
Exited
| Fisher Asset Management | $270,227 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,302 holders, 70.72M shares, $38.50B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.20K sh · $1.17M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology